Figure 1.
Kaplan-Meier estimates in patients treated with rituximab and lenalidomide. (A) Progression-free survival and overall survival in previously untreated cohort (B) Progression-free survival and overall survival in relapsed/refractory cohort
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.